MLICM
CGON icon

Metropolitan Life Insurance Company (MetLife)’s CG Oncology CGON Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,246
Closed -$54.7K – 411
2024
Q1 		$54.7K Buy
+1,246
New +$50.9K ﹤0.01% 1359

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CGON Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of CG Oncology (CGON) in Q2 2024, closing a stake of 1,246 shares — an estimated $54.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CGON in Q1 2024 and held it in 1 quarter. The position peaked at $54.7K in Q1 2024. 111 funds tracked by Wall St. Rank hold CGON as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining CG Oncology position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,246 CG Oncology shares in Q2 2024, an estimated $54.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in CG Oncology in Q1 2024 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s CG Oncology position peaked at $54.7K in Q1 2024.
  • 111 funds tracked by Wall St. Rank held CG Oncology as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.